Morgan Stanley Initiates Coverage On Aeva Technologies with Equal-Weight Rating, Announces Price Target of $11
Today, 9:51 AM
Morgan Stanley analyst Joseph Moore initiates coverage on Aeva Technologies (NYSE:AEVA) with a Equal-Weight rating and announces Price Target of $11.
New Street Research Initiates Coverage On Aeva Technologies with Buy Rating, Announces Price Target of $18
Today, 9:51 AM
New Street Research analyst Pierre Ferragu initiates coverage on Aeva Technologies (NYSE:AEVA) with a Buy rating and announces Price Target of $18.
One In Five Russell 3000 Additions Went Public Via SPAC: What Investors Should Know
Today, 9:51 AM
One of the biggest events for investors last week was the new additions to the Russell 3000 Index. The inclusion in the index means several ETFs have to add shares of the stocks as part of the rebalancing efforts.
10 Information Technology Stocks Showing Unusual Options Activity In Today’s Session
Today, 9:51 AM
This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Unusual trading activity could push option prices to hyperbolic or underperforming levels.
Uncategorized
74 Biggest Movers From Friday
Today, 9:51 AM
Gainers
MoSys, Inc. (NASDAQ: MOSY) shares climbed 50.5% to settle at $4.35 on Friday. MoSys, last week, reported a loss for its first quarter.
Uncategorized
Cramer Advises Viewers On Suncor, Jazz And More
Today, 9:51 AM
On CNBC's "Mad Money Lightning Round," Jim Cramer said that in the energy space he is recommending only Chevron Corporation (NYSE: CVX) and Pioneer Natural Resources Co (N
Uncategorized
Piper Sandler Maintains Overweight on Aeva Technologies, Lowers Price Target to $16
Today, 9:51 AM
Piper Sandler analyst Arvind Ramnani maintains Aeva Technologies (NYSE:AEVA) with a Overweight and lowers the price target from $22 to $16.
Uncategorized
Earnings Scheduled For May 13, 2021
Today, 9:51 AM
Companies Reporting Before The Bell
• CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report quarterly loss at $0.06 per share on revenue of $5.05 million.